LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genomic Assay Predicts Probability of Heart Transplant Rejection

By LabMedica International staff writers
Posted on 05 Mar 2014
Results obtained over time by a gene expression assay used to monitor heart transplant patients for signs of rejection may be able to predict the likelihood of rejection in the future.

The AlloMap Molecular Expression Test, which is manufactured and performed by the biomedical company XDx (Brisbane, CA, USA), is an in vitro diagnostic multivariate index assay (IVDMIA) testing service. The assay, which is performed in a single laboratory, assesses the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing may be used to evaluate transplant patients aged 15 years or older from at least two months after the transplant. It is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.

AlloMap, which measures the expression levels of 11 rejection-related genes from a patient's blood sample, received clearance from the [US] Food and Drug Administration (FDA) in 2008 and it is now routinely used by a majority of American heart transplant centers to monitor low-risk patients during follow-up care, resulting in a substantial reduction in the number of heart-muscle biopsies.

Investigators at the University of California, Los Angeles (USA) recently evaluated data obtained by a study of 600 heart transplant recipients who had been monitored by routine biopsy or with the AlloMap test. They found that the variability of a heart recipient's gene expression profiling test scores over time could provide prognostic utility. This information was independent of the probability of acute cellular rejection at the time of testing.

"The AlloMap was the first FDA-cleared test allowing transplant centers to rule out rejection at the time of the visit," said first author Dr. Mario Deng, professor of medicine at the University of California, Los Angeles. "But until now, it has never been used to predict future events. For the first time, we can use genomic testing over multiple patient visits to go beyond intuition to understand not just how patients are doing now but how they are likely to be a few months from now. It is another step toward personalized medicine."

The study was published in the January 31, 2014, online edition of the journal Transplantation.

Related Links:

XDx 
University of California, Los Angeles 


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA

DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
PURITAN MEDICAL